CVRx Inc
$ 5.03
2.86%
12 Jun - close price
- Market Cap 129,761,000 USD
- Current Price $ 5.03
- High / Low $ 5.04 / 4.81
- Stock P/E N/A
- Book Value 1.10
- EPS -2.01
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -1.07 %
- 52 Week High 11.30
- 52 Week Low 4.37
About
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Analyst Target Price
$11.17
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-12 | 2025-11-05 | 2025-08-04 | 2025-05-08 | 2025-02-04 | 2024-10-29 | 2024-07-29 | 2024-04-30 | 2024-01-25 | 2023-10-26 | 2023-07-25 |
| Reported EPS | -0.5 | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 |
| Estimated EPS | -0.5 | -0.44 | -0.5 | -0.52 | -0.57 | -0.38 | -0.47 | -0.55 | -0.54 | -0.55 | -0.58 | -0.58 |
| Surprise | 0 | -0.02 | 0.01 | -0.05 | 0.04 | -0.05 | -0.1 | -0.1 | -0.5 | 0.11 | 0.15 | 0.02 |
| Surprise Percentage | 0% | -4.5455% | 2% | -9.6154% | 7.0175% | -13.1579% | -21.2766% | -18.1818% | -92.5926% | 20% | 25.8621% | 3.4483% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVRX
2026-06-10 15:09:17
CVRx is undergoing a CFO transition and is focused on expanding its Barostim therapy, which targets a significant U.S. market. The company aims to triple its market opportunity through ongoing clinical trials and expects accelerated adoption and improved financial performance due to enhanced reimbursement and strong Q1 growth. This information is based on the Goldman Sachs 47th Annual Global Healthcare Conference 2026 audio transcript.
2026-06-09 19:40:23
CVRx, Inc. announced that CFO Jared Oasheim will be stepping down from his role after joining the company in 2015. He will remain an advisor until February 2027 while CVRx searches for a successor to lead its finance organization. The company, which develops neuromodulation devices for cardiovascular patients, recently exceeded Q1 2026 earnings expectations and secured Medicare Advantage coverage for its Barostim therapy from Humana.
2026-06-09 14:39:47
Jared Oasheim, CFO of CVRx, Inc. (NASDAQ:CVRX), will be stepping down from his position after a decade with the company to pursue other professional opportunities. Oasheim, who played a key role in the company's IPO and establishing its financial organization, will remain until a successor is found and will serve as an advisor until February 2027. CVRx, a medical device company with a market capitalization of $143 million, is searching for a new CFO and continues to see positive developments for its Barostim device, including strong Q1 2026 earnings and Medicare Advantage coverage from Humana.
2026-06-09 11:38:44
CVRx, Inc. (NASDAQ: CVRX) announced that Jared Oasheim, its Chief Financial Officer, will be stepping down to pursue other professional opportunities. Mr. Oasheim will remain with the company until a successor is appointed and act as an advisor until February 2027 to ensure a smooth transition. The company is initiating a search for his replacement and acknowledged his significant contributions, including leading CVRx through its IPO.
2026-06-09 11:38:44
Jared Oasheim, CFO of CVRx, has announced his resignation to pursue other professional opportunities but will remain with the company through a transition period and serve as a paid consultant. His resignation notice was dated June 7, 2026, and he will continue as CFO until a successor is found, with a full-time employment period extending until at least August 31, 2026, followed by consulting services through February 2027. Oasheim will be eligible for his 2026 cash incentive, receive cash payments totaling $262,000, and be compensated at $245/hour for consulting.
2026-06-09 11:38:44
CVRx, Inc. announced that its Chief Financial Officer, Jared Oasheim, will resign to pursue other professional opportunities. He will remain CFO until a successor is found and will then serve as a consultant through February 2027 to ensure a smooth transition. The company has detailed an Employment Transition Agreement, including compensation for Oasheim's assistance and an extended stock option exercise period.
